Preferences and utilities for the symptoms of moderate to severe allergic asthma
Authors:
- 24 November 2007
- journal article
- Published by Springer Nature in The European Journal of Health Economics
- Vol. 9 (3) , 275-284
Abstract
Patients with moderate to severe allergic asthma have persistent poorly controlled asthma despite inhaled or systemic corticosteroid therapy. New therapies are becoming more widely available to treat such patients, but their value needs to be formally assessed in an economic evaluation. Within a publicly funded health care system such an analysis should reflect societal preferences when measuring treatment benefits. The aim of this study was to elicit societal preferences for the symptom burden associated with moderate to severe allergic asthma. Existing daily symptom diary data from a clinical trial were used to develop health state descriptions for evaluation in a standard gamble interview. Five health states were produced that reflected five distinct levels of control ranging from ‘complete control of asthma’ to ‘worsening of asthma’, as defined by another outcome measure. The symptom diary data were also used as attributes in a discrete choice experiment (DCE) to estimate willingness to pay for improvements in symptoms. Members of the general public (n = 101) completed the interview. Thirteen participants failed the consistency checks and were excluded from the analysis. Societal utility ratings for the health states ranged from 0.71 (worsening of asthma) to 0.78 (complete control of asthma). The participants were also willing to pay £160 a month for the avoidance of all symptoms. The range of utility values (0.71–0.78) demonstrates the severity of moderate to severe allergic asthma. However the spread of scores between complete control of asthma and worsening of asthma was lower than was expected. The community sample placed only a moderate value on the avoidance of all asthma symptoms in the DCE survey. The results suggest that the community sample may not have fully understood the benefits of control over asthma symptoms and the limitations such symptoms can impose on everyday life.Keywords
This publication has 19 references indexed in Scilit:
- Patient preferences for asthma therapy: a discrete choice experimentPrimary Care Respiratory Journal, 2007
- The impact of asthma exacerbations on health-related quality of life in moderate to severe asthma patients in the UKPrimary Care Respiratory Journal, 2007
- Psychometric evaluation of Global Evaluation of Treatment Effectiveness: a tool to assess patients with moderate-to-severe allergic asthmaJournal of Medical Economics, 2007
- A longitudinal prospective study of health-related quality of life in breast cancer patients following high-dose chemotherapy with autologous blood stem cell transplantationBone Marrow Transplantation, 2005
- Benefits of omalizumab as add‐on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATEAllergy, 2004
- Omalizumab improves asthma-related quality of life in patients with severe allergic asthmaJournal of Allergy and Clinical Immunology, 2003
- Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthmaJournal of Allergy and Clinical Immunology, 2001
- Conjoint Preference Elicitation Methods in the Broader Context of Random Utility Theory Preference Elicitation Methods2001
- Variations in population health status: results from a United Kingdom national questionnaire surveyBMJ, 1998
- Estimating the functional form of the independent variables in probit modelsApplied Economics, 1995